Laura Alder

Dr. Laura Alder

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2023 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
LALaura Alder
Laura Alder
Dario TrapaniDario Trapani
Dario Trapani
CBClaire Bradbury
Claire Bradbury
ASAmanda E. D. Van Swearingen
Amanda E. D. Van Swearingen
STSara M. Tolaney
Sara M. Tolaney
SSSarah Sammons
Sarah Sammons
Leptomeningeal metastases (LM) are a devastating complication of HER2 + metastatic breast cancer (MBC), with no effective treatments. In a case series of 8 patients with heavily pretreated HER2 + MBC and progressing LM, all 8 patients (100%) derived clinical benefit from Trastuzumab deruxtecan (TDXd), and 4 patients (50%) had an objective partial response based on formal neuroradiology MRI reads using the EORTC/RANO-LM Revised-Scorecard. T-DXd warrants further study in LM in HER2 + MBC and solid tumors where T-DXd may be active.

31 October 2022 in JCO Precision Oncology
Verified
Journal Article
Open access
SSSarah Sammons
Sarah Sammons
KRKira Raskina
Kira Raskina
NDNatalie Danziger
Natalie Danziger
LALaura Alder
Laura Alder
ASAlexa B. Schrock
Alexa B. Schrock
SCSaranya Chumsri
Saranya Chumsri
PURPOSE: APOBEC mutagenesis underlies somatic evolution and accounts for tumor heterogeneity in several cancers, including breast cancer (BC). In this study, we evaluated the characteristics of a real-world cohort for time-to-treatment discontinuation (TTD) and overall survival on CDK4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) and immune checkpoint inhibitors. METHODS: Comprehensive genomic profiling results from 29,833 BC samples were analyzed for tumor mutational burden and APOBEC signatures. For clinical outcomes, a deidentified nationwide (United States–based) BC Clinico-Genomic Database (CGDB) was evaluated with log-rank and Cox models. Patients with hormone receptor–positive (HR+) human epidermal growth factor receptor 2–negative (HER2–) BC who received first-line ET and CDK4/6i were included. Eligible patients from Mayo Clinic and Duke University were HR+ HER2– BC with sequencing data between September 2013 and July 2020. RESULTS: Of 29,833 samples sequenced, 7.9% were APOBEC+ with a high rate in invasive lobular carcinoma (16.7%) and in metastatic tumors (9.7%) relative to locally biopsied BC (4.3%; P < .001). In CGDB, 857 patients with HR+ HER2– BC received ET plus CDK4/6i in the first line. APOBEC+ patients had significantly shorter TTD on ET plus CDK4/6i than APOBEC– patients, 7.8 (95% CI, 4.3 to 14.6) versus 12.4 months (95% CI, 11.2 to 14.1; hazard ratio, 1.6; 95% CI, 1.03 to 2.39; P = .0036). Clinical benefit to immune checkpoint inhibitors was observed in HR+ HER2–, APOBEC+, tumor mutational burden–high patients, with four of nine CGDB patients (TTD 0.3-11.3 months) and four of six patients in Duke/Mayo cohorts (TTD 0.9-40.5 months) with a TTD of ≥ 3 months. CONCLUSION: APOBEC+ HR+ HER2– patients had shorter TTD on first-line ET plus CDK4/6i relative to APOBEC– patients. Further research is needed to optimize the treatment of APOBEC+ HR+ HER2– BC and to investigate the efficacy of immunotherapeutic strategies in this population.

6 December 2025 in Lung Cancer
Verified
Journal Article
Closed access
BZBingnan Zhang
Bingnan Zhang
LALaura Alder
Laura Alder
SRSamuel Rosner
Samuel Rosner
ADAakash Desai
Aakash Desai
ACAlissa J. Cooper
Alissa J. Cooper
SPSonam Puri
Sonam Puri

1 October 2025 in JCO Precision Oncology
Verified
Journal Article
Closed access
ACAlissa J. Cooper
Alissa J. Cooper
BHBenjamin Herzberg
Benjamin Herzberg
MPMitchell Parma
Mitchell Parma
KWKaiwen Wang
Kaiwen Wang
LALaura Alder
Laura Alder
BZBingnan Zhang
Bingnan Zhang

1 January 2024 in Neuro-Oncology Advances
Verified
Journal Article
Open access
PDF file
LALaura Alder
Laura Alder
GBGloria Broadwater
Gloria Broadwater
MGMichelle Green
Michelle Green
ASAmanda E D Van Swearingen
Amanda E D Van Swearingen
ELEric S Lipp
Eric S Lipp
SSSarah Sammons
Sarah Sammons
Although serum circulating tumor DNA (ctDNA) is routine, data from patients with brain metastases (BrMs) is limited. We assessed genomic alterations in ctDNA from patients with solid tumor BrMs in 3 groups: Isolated BrMs with stable extracranial disease (iCNS), concurrent brain and extracranial progression (cCNS), and extracranial progression with no active BrMs (eCNS). We also compared ctDNA alterations between patients with and without BrMs. Patients with a Guardant360 ctDNA profile with (n = 253) and without BrMs (n = 449) from the Duke Molecular Registry between January 2014 and December 2020 were identified. Actionable alterations were defined as FDA-recognized or standard-of-care biomarkers. Disease status was determined via investigator assessment within 30 days of ctDNA collection. Among the 253 patients with BrMs: 29 (12%) had iCNS, 160 (63%) cCNS, and 64 (25%) eCNS. Breast (BC; 12.0%) and non-small cell lung cancer (NSCLC; 76.4%) were the most common tumor types. ESR1 (60% vs 25%, P < .001) and BRCA2 (17% vs 5%, P = .022) were more frequent in BC BrMs. In NSCLC BrMs, EGFR alterations were most frequent in the iCNS group (iCNS: 67%, cCNS: 40%, eCNS:37%, P = .08) and in patients with BrMs (36% vs 17%, P < .001). Sequencing from both brain tissue and ctDNA were available for 8 patients; 7 (87.5%) had identical alterations. This study illustrates the feasibility of detecting alterations from ctDNA among patients with BrMs. A higher frequency of actionable mutations was observed in ctDNA in patients with BrMs. Additional studies comparing ctDNA and alterations in BrMs tissue are needed to determine if ctDNA can be considered a surrogate to support treatment decisions.

21 June 2025 in Cancers
Verified
Journal Article
Open access
PDF file
DGDiamone Gathers
Diamone Gathers
COCameron Oswalt
Cameron Oswalt
LALaura Alder
Laura Alder
KCKevin Chen
Kevin Chen
JHJordyn P. Higgins
Jordyn P. Higgins
EOEziafa Oduah
Eziafa Oduah
Historically, systemic therapy for resectable non-small cell lung cancer (NSCLC) has been associated with a modest impact on overall survival. The current treatment options for early-stage resectable NSCLC include neoadjuvant, adjuvant, and perioperative immunotherapy in combination with chemotherapy. In this review, we explore the current treatment paradigms and emerging opportunities for improved survival outcomes from using immunotherapeutic approaches in the treatment of early-stage resectable NSCLC. The incorporation of immunotherapy into neoadjuvant, adjuvant, and perioperative treatment of surgically resectable NSCLC has yielded improved outcomes beyond chemotherapy-alone approaches. Despite this, there remains a margin for improving survival outcomes for patients. Clinical trials utilizing novel agents and approaches that modulate the anti-tumor immune response are currently ongoing and will likely inform the future treatment landscape for early-stage surgically resectable NSCLC.